PARP Inhibitor Shows Promise in Patients With BRCA-Mutated Pancreatic Cancer

Main|Search|PHGKB



Last Posted: May 25, 2018

---

• PARP Inhibitor Shows Promise in Patients With BRCA-Mutated Pancreatic Cancer  
  ASCO Post, May 23, 2018
• Direct-to-Consumer Genetic Testing  
  J Gill et al, JAMA, May 18, 2018
• Direct-to-Consumer Genetic Testing - The Implications of the US FDA’s First Marketing Authorization for BRCA Mutation Testing  
  Gill J, et al. JAMA, May 18, 2018
• Prevalence of deleterious mutations among patients with breast cancer referred for multigene panel testing in a Romanian population.  
  Goidescu Iulian Gabriel et al. Clujul medical (1957) 2018 91(2) 157-165
• Risk-reducing mastectomy for the prevention of primary breast cancer.  
  Carbine Nora E et al. The Cochrane database of systematic reviews 2018 4CD002748
• Multigene testing replacing BRCA tests for breast cancer risk  
  Stanford University, May 10, 2018
• Validation of Version 3.0 of the Breast Cancer Genetics Referral Screening Tool (B-RST™).  
  Bellcross Cecelia et al. Genetics in medicine : official journal of the American College of Medical Genetics 2018 May
• Angelina's impact: Advocates Share  
  My Gene Counsel, May 14, 2018
• Beyond BRCA: A Case Series Examining the Advent of Multigene Panel Testing.  
  Reap Leo et al. Clinical breast cancer 2018 Apr
• Effects of Cancer Genetic Panel Testing on at-Risk Individuals.  
  Frost Anja S et al. Obstetrics and gynecology 2018 May

more